MarginsXMarginsX
Home › Markets › Health Care › ESLA

Estrella Immunopharma Inc. (ESLA)

ESLA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3800
-26.07% on the day
Market cap
$16.5M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerESLA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001844417
SEC industry codeBiological Products, (No Diagnostic Substances)

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
0.1 months
$100K cash at June 30, 2026
Share count, 1 year
+17.4%
2025-08-06 to 2026-08-11 · +1906.0% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
$1K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern."
10-Q 2026-08-13
Cash and burn$100K cash; operating cash flow -$2.3M a quarter.Report 2026-06-30
Shares outstanding43,497,864 (2026-08-11); 37,065,589 a year earlier; 2,168,354 three years earlier.Cover page 2026-08-11
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-01-06
Exchange deficiency notices, 12 months3 (8-K item 3.01)8-K 2026-09-08
AuditorMacias Gini & O'Connell LLP, Irvine, California, United StatesPCAOB Form AP 2026-03-23
Late filings, 12 months1 NT noticeNT 10-Q 2026-05-18
Insider trades, 12 monthsBought $1K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$2.3M-$1.8M$100KNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$2.3M-$6.7M$1.9MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2025
2025-12-31
Not filed-$613K-$177K$1.4MNo debt tagsNeeds four quarters10-K 2026-03-18
Q3 2025
2025-09-30
Not filed-$4.8M-$727K$1.6MNo debt tagsNeeds four quarters10-Q 2025-11-12
Q2 2025
2025-06-30
Not filed-$5.5M-$415K$1.3MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$2.1M-$466K$421KNo debt tagsNeeds four quarters10-Q 2026-08-13
Q4 2024
2024-12-31
Not filed-$1.1M-$896K$917KNo debt tagsNeeds four quarters10-K 2026-03-18
Q3 2024
2024-09-30
Not filed-$3.4M-$2.2M$1.8MNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32026-02-13
Latest annual report
AMENDMENT NO. 1 TO FORM 10-K
10-K/A2026-04-30
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-16
Latest current report
CURRENT REPORT
8-K2026-10-29
Latest proxyDEF 14A2026-05-27

Source: SEC EDGAR submissions feed, 260 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+37.1%
1 month+63.7%
3 months-29.1%
Year to date-67.1%
1 year-76.6%
From 52-week high-77.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
ESLAWEstrella Immunopharma Inc. Warrant$0.0878

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ABOSAcumen Pharmaceuticals Inc.$0.2160+0.93%$15.6M
PLURPluri Inc.$1.04-0.95%$15.0M
BSEMBioStem Technologies Inc.$0.9601-8.56%$18.4M
ATYRaTyr Pharma Inc.$5.24-14.17%$13.4M
PASGPassage Bio Inc.$4.13-2.82%$13.3M
JSPRJasper Therapeutics Inc.$11.77-13.96%$13.1M
DYAIDyadic International Inc.$0.3200-2.14%$12.8M
BCDABioCardia Inc.$0.7901-4.92%$12.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier